Oral JAK inhibitors are preferred first-line long-term therapy for severe adult AA; FDA-approved agents are favored, whereas dupilumab is an alternative for patients with comorbid atopy. Experts ...
One of the most common misconceptions Feldman encounters among patients and caregivers is that eczema is simply a problem of ...
The FDA has accepted Lynch Regenerative Medicine’s (LRM) investigational new drug (IND) application for a phase 2b clinical ...
ORKA-001 achieved PASI 100 in 61% of high-dose patients at week 16 in the phase 2b EVERLAST-B trial of moderate-to-severe ...
In "Transitioning From Self-Injection to HCP-Administered Psoriasis Therapy," our experts examine what to do when a patient ...
Aldredge called Horizons in Advanced Practice one of the most profound meetings for newer dermatology NPs and PAs. The intimate audience setting gives attendees access to updated, evidence-based ...
Menopause can bring dryness, sensitivity, acne, and loss of firmness, requiring dermatologists to adapt skin care to patients ...
Lutikizumab (ABT-981) met its primary end point and all 8 ranked secondary end points in the phase 3 INTREPID trial ...
Merck. Moderna & Merck announce 5-year data for intismeran autogene in combination with KEYTRUDA (pembrolizumab) demonstrated sustained improvement in recurrence-free survival in patients with ...
Preview the trial data dermatology NPs and PAs will dissect in small-group sessions on AD, psoriasis, and type 2 disease at Horizons in Advanced Practice.
At the 2026 Horizons in Advanced Practice meeting, Omar Noor, MD, discussed viewing atopic dermatitis patients as type 2 inflammatory patients, growth curve data, and recent hidradenitis suppurativa ...
Dermatology Times will host its 3rd annual Horizons in Advanced Practice meeting on October 23, 2026, in Atlanta, Georgia.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results